Collaboration aims to develop model clinics and strengthen capacity of healthcare professionals in management of obesity ...

The number of reported measles cases in the United States has hit 1,288 in the first six months of this year, the most since ...

Novo Nordisk's beaten-down valuation became too attractive to pass up, so I bought the stock earlier this year. Eli Lilly's ...

EUROPEAN shares closed at a four-week high on Wednesday, with banks the biggest boost as investors awaited signs of progress ...

Hims and Hers announced this morning that it will begin offering compounded semaglutide (generic Ozempic or Wegovy) for $199 ...

Shares climbed approximately 2.4–2.7%, touching highs between $163.93 (£120.58) and $164.37 (£120.90) before pulling back to ...

U.S. telehealth upstart Hims & Hers Health, Inc. is planning to enter the Canadian market with an eye to selling generic ...

Hims & Hers announced plans to expand its weight loss program to Canada in 2026 in connection with the availability of generic semaglutide anywhere in the world.

Hims and Hers Health is planning to cash in on Novo Nordisk losing its semaglutide drug exclusivity in Canada. The telehealth ...

The Hims & Hers wellness platform announced Wednesday it will soon offer a generic version of the weight loss drug ...

The move follows a dramatic breakup in June between Hims & Hers and Danish drug maker Novo Nordisk, which makes the brand name weight loss drug Wegovy. Novo Nordisk accused the Hims & Hers of ...